Skip to main content

How does carboplatin stop cancer?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Oct 9, 2023.

Official answer

by Drugs.com

Carboplatin is a chemotherapy drug that stops cancer cell growth by binding to the cell DNA and preventing it’s replication.

Carboplatin is classified as an alkylating agent and platinum-containing compound. It is not cell-cycle specific, meaning that it kills cancer cells when they are at rest, not actively dividing.

Carboplatin is usually given by an intravenous (IV) infusion into a vein. Your will receive this medicine in cycles over a period of time, typically every 4 weeks, in a clinic. In between cycles, your body will rest and recuperate from the treatment.

Which cancer does carboplatin treat?

Carboplatin is used together with other cancer drugs to treat advanced ovarian cancer. It may be used in ovarian cancer that has never been treated or cancer that has come back after treatment with other anticancer drugs.

Carboplatin is usually combined with another platinum-type cancer drug called paclitaxel to treat ovarian cancer. It is a commonly used combination as it has been shown to help patients live longer over other ovarian cancer treatments.

Your doctor may decide to give you carboplatin to treat other types of cancer, such as lung, anal, bladder, breast or head and neck cancer, among others. For some uses, this is called an “off-label” use.

  • "Off-label" use of a drug refers to when a doctor prescribes a drug for a different purpose than those formally approved by the FDA and found in the package labeling of the drug.
  • Your doctor may decide to use carboplatin for other cancers when they believe it will be helpful for you and there is adequate clinical information and experience.
  • You may receive carboplatin in combination with other treatments.

Related Questions

Learn more

This is not all the information you need to know about carboplatin for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the product information and discuss any questions you have with your doctor or other health care provider.

References

Read next

Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading

A hereditary family history of lung cancer is one of the many risk factors for developing non-small cell lung cancer. About 8% of lung cancers are thought to be inherited or linked to gene changes, but smoking and air pollution remain the primary causes of lung cancer. Continue reading

Non-small cell lung cancer (NSCLC) tends to spread more slowly than small cell lung cancer (SCLC). About 80% of all lung cancers are diagnosed as NSCLC. Some forms of NSCLC do grow rapidly, such as large cell undifferentiated carcinoma and large cell neuroendocrine carcinoma. Lung cancer most commonly spreads to the liver, brain, bones or adrenal glands. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer